PATENT CLAIM ANALYSIS

Application Number: 16123886
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-04
Patent Classification: ["514", "601000"]

Abstract:
The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: as defined in the specification. The invention is also directed to compositions containing and uses of the compounds of formula I.

Claim (Index 31):
A method for the treatment or prevention in a mammal of a condition selected from the group consisting of acute neurological and psychiatric disorders, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, Huntington's Chorea, amyotrophic lateral sclerosis, ocular damage, retinopathy, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, migraine, urinary incontinence, substance tolerance, substance withdrawal, anxiety, trigeminal neuralgia, hearing loss, tinnitus, macular degeneration of the eye, emesis, brain edema, pain, tardive dyskinesia, sleep disorders, and conduct disorder, comprising administering a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein each R 1  and each R 2  and each R 7  is independently selected from the group consisting of hydrogen, halogen, hydroxyl, \u2014CF 3 , \u2014CN, \u2014(C\u2550O)R 8 , \u2014O\u2014(C\u2550O)\u2014R 8 , \u2014(NR 8 )\u2014(C\u2550O)\u2014R 8 , \u2014(C\u2550O)\u2014OR 8 , \u2014(C\u2550O)\u2014N(R 8 ) 2 , \u2014OR 8 , \u2014O\u2014(C\u2550O)\u2014OR 8 , \u2014O\u2014(C\u2550O)\u2014N(R 8 ) 2 , \u2014NO 2 , \u2014N(R 8 ) 2 , \u2014(NR 8 )\u2014SO 2 \u2014R 8 , \u2014S(O) w R 8 , \u2014SO 2 \u2014N(R 8 ) 2 , (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 9 )heterocycloalkyl, and (C 3 -C 10 )cycloalkyl; wherein said (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 9 )heterocycloalkyl, or (C 3 -C 10 )cycloalkyl are each independently optionally substituted with one, two, three or four R 9 ; w is 0, 1 or 2; m is zero, one, two or three; n is zero, one, two or three; p is zero, one, two or three; q is zero, one, two or three; s is one and t is one; or one of s or t is one and the other of s or t is two; R 3  is hydrogen or (C 1 -C 6 )alkyl; each R 4  is independently selected from hydrogen, or (C 1 -C 6 )alkyl; wherein said (C 1 -C 6 )alkyl may be optionally substituted with one, two, three or four halogen, \u2014CN, or \u2014OR 9 ; or two R 4  groups on the same carbon atom may be taken together to form an oxo (\u2550O) radical or a (C 3 -C 6 )spirocycloalkyl; R 5  is hydrogen, or (C 1 -C 6 )alkyl; R 6  is (C 1 -C 6 )alkyl-(C\u2550O)\u2014, [(C 1 -C 6 )alkyl] 2 N\u2014(C\u2550O)\u2014, (C 1 -C 6 )alkyl-SO 2 \u2014, (C 3 -C 10 )cycloalkyl-SO 2 \u2014, or [(C 1 -C 6 )alkyl] 2 N\u2014SO 2 \u2014; wherein said (C 1 -C 6 )alkyl moieties of said [(C 1 -C 6 )alkyl] 2 N\u2014(C\u2550O)\u2014 and [(C 1 -C 6 )alkyl] 2 N\u2014SO 2 \u2014 may optionally be taken together with the nitrogen atom to which they are attached to form a four to six membered heterocyclic ring; R 8  is independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 9 )heterocycloalkyl, and (C 3 -C 10 )cycloalkyl; wherein said (C 1 -C 6 )alkyl may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, \u2014CN, perfluoro(C 1 -C 6 )alkyl, hydroxy, amino, (C 1 -C 6 )alkylamino, [(C 1 -C 6 )alkyl] 2 amino, (C 1 -C 6 )alkoxy, perfluoro(C 1 -C 6 )alkoxy, HO\u2014(C\u2550O)\u2014, (C 1 -C 6 )alkyl-O\u2014(C\u2550O)\u2014, formyl, (C 1 -C 6 )alkyl-(C\u2550O)\u2014, H 2 N\u2014(C\u2550O)\u2014, (C 1 -C 6 )alkyl]-(NH)\u2014(C\u2550O)\u2014, [(C 1 -C 6 )alkyl] 2 N\u2014(C\u2550O)\u2014, (C 1 -C 6 )alkyl-(C\u2550O)\u2014O\u2014, H(C\u2550O)\u2014NH\u2014, (C 1 -C 6 )alkyl(C\u2550O)\u2014NH\u2014, (C 1 -C 6 )alkyl(C\u2550O)\u2014[N((C 1 -C 6 )alkyl)]-, (C 1 -C 6 )alkyl-SO 2 \u2014, (C 1 -C 6 )alkyl-SO 2 \u2014NH\u2014, (C 1 -C 6 )alkyl-SO 2 \u2014[N((C 1 -C 6 )alkyl)]-, H 2 N\u2014SO 2 \u2014, [(C 1 -C 6 )alkyl]-NH\u2014SO 2 \u2014, and [(C 1 -C 6 )alkyl] 2 N\u2014SO 2 \u2014; wherein said (C 1 -C 6 )alkyl may be additionally optionally substituted with an optionally substituted (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 9 )heterocycloalkyl, or (C 3 -C 10 )cycloalkyl; wherein said optional substituents may be independently selected from one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF 3 , \u2014CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, and amino; wherein each of said R 8  (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 9 )heterocycloalkyl or (C 3 -C 10 )cycloalkyl substituents may be optionally additionally substituted with one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF 3 , \u2014CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy and amino; each R 9  is independently selected from the group consisting of halogen, hydroxyl, \u2014CF 3 , \u2014CN, \u2014(C\u2550O)R 10 , \u2014O\u2014(C\u2550O)\u2014R 10 , \u2014(NR 10 )\u2014(C\u2550O)\u2014R 10 , \u2014(C\u2550O)\u2014OR 10 , \u2014(C\u2550O)\u2014N(R 10 ) 2 , \u2014OR 10 , \u2014O\u2014(C\u2550O)\u2014OR 10 , \u2014O\u2014(C\u2550O)\u2014N(R 10 ) 2 , \u2014NO 2 , \u2014N(R 10 ) 2 , \u2014(NR 10 )\u2014SO 2 \u2014R 10 , \u2014S(O) u R 10 , \u2014SO 2 \u2014N(R 10 ) 2 , R 10  is independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 9 )heterocycloalkyl and (C 3 -C 10 )cycloalkyl; wherein said (C 1 -C 6 )alkyl may be optionally substituted with one, two or three substituents independently selected from hydrogen, halo, \u2014CN, perfluoro(C 1 -C 6 )alkyl, hydroxy, amino, (C 1 -C 6 )alkylamino, [(C 1 -C 6 )alkyl] 2 amino, (C 1 -C 6 )alkoxy, perfluoro(C 1 -C 6 )alkoxy, HO\u2014(C\u2550O)\u2014, (C 1 -C 6 )alkyl-O\u2014(C\u2550O)\u2014, formyl, (C 1 -C 6 )alkyl-(C\u2550O)\u2014, H 2 N\u2014(C\u2550O)\u2014, (C 1 -C 6 )alkyl]-(NH)\u2014(C\u2550O)\u2014, [(C 1 -C 6 )alkyl] 2 N\u2014(C\u2550O)\u2014, (C 1 -C 6 )alkyl-(C\u2550O)\u2014O\u2014, H(C\u2550O)\u2014NH\u2014, (C 1 -C 6 )alkyl(C\u2550O)\u2014NH\u2014, (C 1 -C 6 )alkyl(C\u2550O)\u2014[N((C 1 -C 6 )alkyl)]-, (C 1 -C 6 )alkyl-SO 2 \u2014, (C 1 -C 6 )alkyl-SO 2 \u2014NH\u2014, (C 1 -C 6 )alkyl-SO 2 \u2014[N((C 1 -C 6 )alkyl)]-, H 2 N\u2014SO 2 \u2014, [(C 1 -C 6 )alkyl]-NH\u2014SO 2 \u2014, and [(C 1 -C 6  alkyl] 2 N\u2014SO 2 \u2014; wherein said (C 1 -C 6 )alkyl may also be additionally optionally substituted with an optionally substituted (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 1 -C 9 )heterocycloalkyl or (C 3 -C 10 )cycloalkyl; wherein said optional substituents may be independently selected from one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF 3 , \u2014CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, and amino; wherein each of said R 10  (C 6 \u2014C)aryl, (C 1 -C 2 )heteroaryl, (C 1 -C 2 )heterocycloalkyl, or (C 3 -C 10 )cycloalkyl substituents may be optionally additionally substituted with one, two, three or four radicals independently selected from halogen, hydroxyl, \u2014CF 3 , \u2014CN, (C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, and amino; R 11  is hydrogen or (C 1 -C 6 )alkyl; ring \u201cA\u201d is (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 4 -C 10 )cycloalkyl, or (C 1 -C 9 )heterocycloalkyl; wherein two of said R 1  substituents on said (C 4 -C 10 )cycloalkyl and (C 1 -C 9 )heterocycloalkyl may optionally be attached to the same carbon atom and may optionally be taken together to be oxo; ring \u201cB\u201d is (C 6 -C 10 )aryl, (C 1 -C 9 )heteroaryl, (C 4 -C 10 )cycloalkyl, or (C 1 -C 9 )heterocycloalkyl; \u201cX\u201d is \u2014O\u2014 or >C(R 4 ) 2 ; \u201cY\u201d is absent, >NR 11 , \u2014(NR 11 )\u2014(C\u2550O)\u2014, >C\u2550O, \u2014O\u2014 or >C(R 7 ) 2 ; and \u201cZ\u201d is \u2014O\u2014, \u2014S\u2014, \u2014(S\u2550O)\u2014, or \u2014(SO 2 )\u2014 to the mammal.

Metadata:
- Claim Count in Document: 84.0
- Percentile: 97.0
- Lexical Diversity: 1.63333
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13596492', '12823224', '15318207', '14549848', '12525095']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7567577921850215
- 35 USC 102 Novelty (BERT): 0.5669698831146625
- Combined Prediction Score: 0.7377790012779857
- Mean Citation Score: 360.57902
- Max Citation Score: 475.453
- Similarity Product: 324.5880970494747

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test